Physician profile
Dbora Lee
NPI 1013506146
$14,763.45
in general payments reported to CMS, 2019-2025
27 companies · $7,154 in 2025
The $7,154 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $952 · 2023: $2,073 · 2024: $4,585 · 2025: $7,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,420 · Education: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,700.01 |
| Consulting Fee | $2,420.00 |
| Education | $691.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,241.74 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $2,050.56 | 2022-2025 | Opzelura, Opzelura |
| Abbvie INC. | $1,750.75 | 2022-2025 | |
| Dermavant Sciences, INC. | $1,182.65 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $1,069.59 | 2022-2025 | |
| Janssen Biotech, INC. | $951.73 | 2023-2025 | Tremfya |
| Genzyme Corporation | $779.07 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $775.88 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $575.73 | 2023-2025 | Absorica Ld, Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $557.21 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $490.07 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Allergan, INC. | $486.47 | 2022 | |
| Lilly USA, LLC | $326.71 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $275.93 | 2024-2025 | Zoryve |
| Pfizer INC. | $234.73 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $178.69 | 2023-2025 | Ycanth |
| Revance Therapeutics, INC. | $166.44 | 2024-2025 | Daxxify, Daxi |
| Organon LLC | $159.02 | 2025 | Vtama |
| Merz North America, INC. | $142.33 | 2024 | |
| Genentech USA, INC. | $120.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Mayne Pharma Commercial LLC | $39.23 | 2022-2023 | |
| Leo Pharma INC. | $36.43 | 2024-2025 | Adbry, Anzupgo |
| Convatec INC. | $34.55 | 2025 | |
| Amgen INC. | $23.80 | 2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.51 | 2023 | Jublia, Duobrii, Arazlo |
| Botanix Sb INC | $15.17 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dbora Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.